Abstract
Neuroendocrine tumors (NETs) are rare and represent a diverse collection of malignancies that occur in many organ systems throughout the body, including the gastrointestinal and respiratory tracts. Unfortunately, the majority of patients with NETs have hepatic metastases at the time of diagnosis. Although some patients may be asymptomatic, others have unusual clinical presentations and variable tumor growth patterns. Although many patients have long indolent courses, without treatment, most patients die within 5 years of diagnosis. This article reviews the care of patients with NETs and hepatic metastases, with emphasis on the increasingly important role of oncologic image-guided interventions.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Brachytherapy
-
Catheter Ablation
-
Chemoembolization, Therapeutic
-
Clinical Trials as Topic
-
Cryosurgery
-
Ethanol / administration & dosage
-
Hepatectomy
-
Humans
-
Liver Neoplasms / diagnostic imaging
-
Liver Neoplasms / pathology
-
Liver Neoplasms / secondary*
-
Liver Neoplasms / therapy*
-
Liver Transplantation
-
Neoplasms, Unknown Primary / diagnosis
-
Neoplasms, Unknown Primary / diagnostic imaging
-
Neoplasms, Unknown Primary / pathology
-
Neoplasms, Unknown Primary / therapy*
-
Neuroendocrine Tumors / diagnosis
-
Neuroendocrine Tumors / diagnostic imaging
-
Neuroendocrine Tumors / pathology
-
Neuroendocrine Tumors / therapy*
-
Practice Guidelines as Topic
-
Radiology, Interventional
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Ethanol